BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours (British Journal of Cancer (2008) 98 (571-579) doi: 10.1038/sj.bjc.6604181);BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours

British Journal of Cancer

Volumn 98, Issue 3, 2008, Pages 571-579

  D'Arcy, V ^a,c   Pore, N ^a   Docquier, F ^a   Abdullaev, Z K ^b   Chernukhin, I ^a   Kita, G X ^a   Rai, S ^a   Smart, M ^a   Farrar, D ^b   Pack, S ^b   Lobanenkov, V ^b   Klenova, E ^a  

^a UNIVERSITY OF ESSEX   (United Kingdom)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

BORIS; Breast cancer; CTCF; Oestrogen receptor; Progesterone receptor

Indexed keywords

BROTHER OF THE REGULATOR OF IMPRINTED SITES PROTEIN; CANCER TESTIS ANTIGEN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR CTCF; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST CELL; CANCER CELL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TISSUE LEVEL; WESTERN BLOTTING;

EID: 38949136330     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604255     Document Type: Erratum

References (46)

1. Abbott A (1999) A post-genomic challenge: learning to read patterns of protein synthesis. Nature 402: 715-720
2. Anderson E (2002) The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Res 4: 197-201
3. Barrett A, Madsen B, Copier J, Lu PJ, Cooper L, Scibetta AG, Burchell J, Taylor-Papadimitriou J (2002) PLU-1 nuclear protein, which is upregulated in breast cancer, shows restricted expression in normal human adult tissues: a new cancer/testis antigen? Int J Cancer 101: 581-588
4. Barron A, Bermejo L, Castro I (1997) [Estrogen receptors and the mammary gland]. Rev Invest Clin 49: 515-528
5. Beck T, Weller EE, Weikel W, Brumm C, Wilkens C, Knapstein PG (1995) Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1. Gynecol Oncol 57: 96-104
6. Chen C, Okayama H (1987) High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 7: 2745-2752
7. Chitale DA, Jungbluth AA, Marshall DS, Leitao MM, Hedvat CV, Kolb D, Spagnoli GC, Iversen K, Soslow RA (2005) Expression of cancer-testis antigens in endometrial carcinomas using a tissue microarray. Mod Pathol 18: 119-126
8. Ciaparrone M, Yamamoto H, Yao Y, Sgambato A, Cattoretti G, Tomita N, Monden T, Rotterdam H, Weinstein IB (1998) Localization and expression of p27KIP1 in multistage colorectal carcinogenesis. Cancer Res 58: 114-122
9. Clarke C, Titley J, Davies S, O'Hare MJ (1994) An immunomagnetic separation method using superparamagnetic (MACS) beads for large-scale purification of human mammary luminal and myoepithelial cells. Epithelial Cell Biol 3: 38-46
10. Cuthill S, Agarwal P, Sarkar S, Savelieva E, Reznikoff CA (1999) Dominant genetic alterations in immortalization: role for 20q gain. Genes Chromosomes Cancer 26: 304-311
11. D'Arcy V, Abdullaev ZK, Pore N, Docquier F, Torrano V, Chernukhin I, Smart M, Farrar D, Metodiev M, Fernandez N, Richard C, Delgado MD, Lobanenkov V, Klenova E (2006) The potential of BORIS detected in the leukocytes of breast cancer patients as an early marker of tumorigenesis. Clin Cancer Res 12: 5978-5986
12. De Vivo I, Huggins GS, Hankinson SE, Lescault PJ, Boezen M, Colditz GA, Hunter DJ (2002) A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. Proc Natl Acad Sci USA 99: 12263-12268
13. deConinck EC, McPherson LA, Weigel RJ (1995) Transcriptional regulation of estrogen receptor in breast carcinomas. Mol Cell Biol 15: 2191-2196
14. Eccles S, Paon L, Sleeman J (2007) Lymphatic metastasis in breast cancer: importance and new insights into cellular and molecular mechanisms. Clin Exp Metastasis 24: 619-636
15. Egland KA, Kumar V, Duray P, Pastan I (2002) Characterization of overlapping XAGE-1 transcripts encoding a cancer testis antigen expressed in lung, breast, and other types of cancers. Mol Cancer Ther 1: 441-450
16. Gaffney EV (1982) A cell line (HBL-100) established from human breast milk. Cell Tissue Res 227: 563-568
17. Ghochikyan A, Mkrtichyan M, Loukinov D, Mamikonyan G, Pack SD, Movsesyan N, Ichim TE, Cribbs DH, Lobanenkov VV, Agadjanyan MG (2007) Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites. J Immunol 178: 566-573
18. Hoffmann MJ, Muller M, Engers R, Schulz WA (2006) Epigenetic control of CTCFL/BORIS and OCT4 expression in urogenital malignancies. Biochem Pharmacol 72: 1577-1588
19. Hong JA, Kang Y, Abdullaev Z, Flanagan PT, Pack SD, Fischette MR, Adnani MT, Loukinov DI, Vatolin S, Risinger JI, Custer M, Chen GA, Zhao M, Nguyen DM, Barrett JC, Lobanenkov VV, Schrump DS (2005) Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res 65: 7763-7774
20. Huggins GS, Wong JY, Hankinson SE, De Vivo I (2006) GATA5 activation of the progesterone receptor gene promoter in breast cancer cells is influenced by the +331G/A polymorphism. Cancer Res 66: 1384-1390
21. Humphreys RC, Lydon J, O'Malley BW, Rosen JM (1997) Mammary gland development is mediated by both stromal and epithelial progesterone receptors. Mol Endocrinol 11: 801-811
22. Janz M, Harbeck N, Dettmar P, Berger U, Schmidt A, Jurchott K, Schmitt M, Royer HD (2002) Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int J Cancer 97: 278-282
23. Jelinic P, Shaw P (2007) Loss of imprinting and cancer. J Pathol 211: 261-268
24. Jelinic P, Stehle JC, Shaw P (2006) The testis-specific factor CTCFL cooperates with the protein methyltransferase PRMT7 in H19 imprinting control region methylation. PLoS Biol 4: e355
25. Jungbluth AA, Busam KJ, Kolb D, Iversen K, Coplan K, Chen YT, Spagnoli GC, Old LJ (2000a) Expression of MAGE-antigens in normal tissues and cancer. Int J Cancer 85: 460-465
26. Jungbluth AA, Stockert E, Chen YT, Kolb D, Iversen K, Coplan K, Williamson B, Altorki N, Busam KJ, Old LJ (2000b) Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours. Br J Cancer 83: 493-497
27. Kalejs M, Erenpreisa J (2005) Cancer/testis antigens and gametogenesis: a review and 'brain-storming' session. Cancer Cell Int 5: 4
28. Klenova EM, Morse III HC, Ohlsson R, Lobanenkov VV (2002) The novel BORIS + CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer. Semin Cancer Biol 12: 399-414
29. Klenova EM, Nicolas RH, Paterson HF, Carne AF, Heath CM, Goodwin GH, Neiman PE, Lobanenkov VV (1993) CTCF, a conserved nuclear factor required for optimal transcriptional activity of the chicken c-myc gene, is an 11-Zn-finger protein differentially expressed in multiple forms. Mol Cell Biol 13: 7612-7624
30. Loukinov D, Ghochikyan A, Mkrtichyan M, Ichim TE, Lobanenkov VV, Cribbs DH, Agadjanyan MG (2006) Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant. J Cell Biochem 98: 1037-1043
31. Loukinov DI, Pugacheva E, Vatolin S, Pack SD, Moon H, Chernukhin I, Mannan P, Larsson E, Kanduri C, Vostrov AA, Cui H, Niemitz EL, Rasko JE, Docquier FM, Kistler M, Breen JJ, Zhuang Z, Quitschke WW, Renkawitz R, Klenova EM, Feinberg AP, Ohlsson R, Morse III HC, Lobanenkov VV (2002) BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proc Natl Acad Sci USA 99: 6806-6811
32. Medina D (2005) Mammary developmental fate and breast cancer risk. Endocr Relat Cancer 12: 483-495
33. Montero Girard G, Vanzulli SI, Cerliani JP, Bottino MC, Bolado J, Vela J, Becu-Villalobos D, Benavides F, Gutkind S, Patel V, Molinolo A, Lanari C (2007) Association of estrogen receptor-alpha and progesterone receptor A expression with hormonal mammary carcinogenesis: role of the host microenvironment. Breast Cancer Res 9: R22
34. Old LJ (2001) Cancer/testis (CT) antigens - a new link between gametogenesis and cancer. Cancer Immunol 1: 1
35. Otte M, Zafrakas M, Riethdorf L, Pichlmeier U, Loning T, Janicke F, Pantel K (2001) MAGE-A gene expression pattern in primary breast cancer. Cancer Res 61: 6682-6687
36. Renaud S, Pugacheva EM, Delgado MD, Braunschweig R, Abdullaev Z, Loukinov D, Benhattar J, Lobanenkov V (2007) Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors. Nucleic Acids Res, [Epub ahead of print]
37. Risinger JI, Chandramouli GV, Maxwell GL, Custer M, Pack S, Loukinov D, Aprelikova O, Litzi T, Schrump DS, Murphy SK, Berchuck A, Lobanenkov V, Barrett JC (2007) Global expression analysis of cancer/testis genes in uterine cancers reveals a high incidence of BORIS expression. Clin Cancer Res 13: 1713-1719
38. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT (2002) Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 188: 22-32
39. Scanlan MJ, Simpson AJ, Old LJ (2004) The cancer/testis genes: review, standardization, and commentary. Cancer Immunol 4: 1
40. Stamps AC, Davies SC, Burman J, O'Hare MJ (1994) Analysis of proviral integration in human mammary epithelial cell lines immortalized by retroviral infection with a temperature-sensitive SV40 T-antigen construct. Int J Cancer 57: 865-874
41. Tanner MM, Tirkkonen M, Kallioniemi A, Collins C, Stokke T, Karhu R, Kowbel D, Shadravan F, Hintz M, Kuo WL, Waldman FM, Isola JJ, Gray JW, Kallioniemi O-P (1994) Increased copy number at 20q13 in breast cancer: defining the critical region and exclusion of candidate genes. Cancer Res 54: 4257-4260
42. Theurillat JP, Zurrer-Hardi U, Varga Z, Storz M, Probst-Hensch NM, Seifert B, Fehr MK, Fink D, Ferrone S, Pestalozzi B, Jungbluth AA, Chen YT, Jager D, Knuth A, Moch H (2007) NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy. Cancer Immunol Immunother 56(11): 1723-1731
43. Tobler NE, Detmar M (2006) Tumor and lymph node lymphangiogenesis - impact on cancer metastasis. J Leukoc Biol 80: 691-696
44. Tong D, Schneeberger C, Czerwenka K, Schmutzler RK, Speiser P, Kucera E, Concin N, Kubista E, Leodolter S, Zeillinger R (1999) Messenger RNA determination of estrogen receptor, progesterone receptor, pS2, and plasminogen activator inhibitor-1 by competitive reverse transcription-polymerase chain reaction in human breast cancer. Clin Cancer Res 5: 1497-1502
45. Vatolin S, Abdullaev Z, Pack SD, Flanagan PT, Custer M, Loukinov DI, Pugacheva E, Hong JA, Morse III H, Schrump DS, Risinger JI, Barrett JC, Lobanenkov VV (2005) Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res 65: 7751-7762
46. Zhao L, Mou DC, Leng XS, Peng JR, Wang WX, Huang L, Li S, Zhu JY (2004) Expression of cancer-testis antigens in hepatocellular carcinoma. World J Gastroenterol 10: 2034-2038